Abstract
Background/Aims: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treatment alone have not been well established in the treatment of mild to moderate ulcerative colitis (UC). We evaluated the clinical course of Korean UC patients treated with 5-ASA/sulfasalazine as a maintenance therapy in terms of relapse and predictive factors of clinical relapse. Methodology: A total 256 UC patients, treated with 5-ASA/sulfasalazine at the Severance Hospital between January 2000 and December 2008, were analyzed retrospectively. We sought to investigate relapse rates and to determine independent predictors for relapse. Results: Of the 256 patients, 127 patients (49.6%) had a disease relapse. The cumulative relapse rate was 21.5% after 1 year, 36.5% after 2 years, 46.9% after 3 years and 59.8% after 5 years. On multivariate analysis, left-sided or extensive colitis at diagnosis (hazard ratio=1.46; 95% CI=1.01-2.10; p=0.04) and initial hemoglobin level <10.5g/dL (hazard ratio=0.43; 95% CI=0.22-0.81; p=0.01) were found to be independent factors for clinical relapse. Conclusions: Our study showed that both disease extent at diagnosis and anemia were major predictive factors for clinical relapse after 5-ASA/sulfasalazine therapy for Korean patients with mild to moderate UC.
| Original language | English |
|---|---|
| Pages (from-to) | 1415-1420 |
| Number of pages | 6 |
| Journal | Hepato-Gastroenterology |
| Volume | 59 |
| Issue number | 117 |
| DOIs | |
| Publication status | Published - 2012 Jul 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology
Cite this
}
Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. / Lee, Hyunjung; Jung, Eun Suk; Lee, Jin Ha; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho; Cheon, JaeHee.
In: Hepato-Gastroenterology, Vol. 59, No. 117, 01.07.2012, p. 1415-1420.Research output: Contribution to journal › Article
TY - JOUR
T1 - Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis
AU - Lee, Hyunjung
AU - Jung, Eun Suk
AU - Lee, Jin Ha
AU - Hong, Sung Pil
AU - Kim, Tae Il
AU - Kim, Won Ho
AU - Cheon, JaeHee
PY - 2012/7/1
Y1 - 2012/7/1
N2 - Background/Aims: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treatment alone have not been well established in the treatment of mild to moderate ulcerative colitis (UC). We evaluated the clinical course of Korean UC patients treated with 5-ASA/sulfasalazine as a maintenance therapy in terms of relapse and predictive factors of clinical relapse. Methodology: A total 256 UC patients, treated with 5-ASA/sulfasalazine at the Severance Hospital between January 2000 and December 2008, were analyzed retrospectively. We sought to investigate relapse rates and to determine independent predictors for relapse. Results: Of the 256 patients, 127 patients (49.6%) had a disease relapse. The cumulative relapse rate was 21.5% after 1 year, 36.5% after 2 years, 46.9% after 3 years and 59.8% after 5 years. On multivariate analysis, left-sided or extensive colitis at diagnosis (hazard ratio=1.46; 95% CI=1.01-2.10; p=0.04) and initial hemoglobin level <10.5g/dL (hazard ratio=0.43; 95% CI=0.22-0.81; p=0.01) were found to be independent factors for clinical relapse. Conclusions: Our study showed that both disease extent at diagnosis and anemia were major predictive factors for clinical relapse after 5-ASA/sulfasalazine therapy for Korean patients with mild to moderate UC.
AB - Background/Aims: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treatment alone have not been well established in the treatment of mild to moderate ulcerative colitis (UC). We evaluated the clinical course of Korean UC patients treated with 5-ASA/sulfasalazine as a maintenance therapy in terms of relapse and predictive factors of clinical relapse. Methodology: A total 256 UC patients, treated with 5-ASA/sulfasalazine at the Severance Hospital between January 2000 and December 2008, were analyzed retrospectively. We sought to investigate relapse rates and to determine independent predictors for relapse. Results: Of the 256 patients, 127 patients (49.6%) had a disease relapse. The cumulative relapse rate was 21.5% after 1 year, 36.5% after 2 years, 46.9% after 3 years and 59.8% after 5 years. On multivariate analysis, left-sided or extensive colitis at diagnosis (hazard ratio=1.46; 95% CI=1.01-2.10; p=0.04) and initial hemoglobin level <10.5g/dL (hazard ratio=0.43; 95% CI=0.22-0.81; p=0.01) were found to be independent factors for clinical relapse. Conclusions: Our study showed that both disease extent at diagnosis and anemia were major predictive factors for clinical relapse after 5-ASA/sulfasalazine therapy for Korean patients with mild to moderate UC.
UR - http://www.scopus.com/inward/record.url?scp=84865185595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865185595&partnerID=8YFLogxK
U2 - 10.5754/hge10680
DO - 10.5754/hge10680
M3 - Article
VL - 59
SP - 1415
EP - 1420
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 117
ER -